Drug Profile
Stable glucagon - Albireo Pharma
Alternative Names: BIOD-961; BIOD-962; BIOD-Stable Glucagon; EZMix; EZMix-GEM program; Glucagon rescue GEM; Glucagon rescue Glucagon Emergency Management program; Injectable stable glucagon - Albireo PharmaLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Biodel
- Developer Albireo Pharma
- Class Antihypoglycaemics; Pancreatic hormones
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypoglycaemia
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 28 Jan 2018 No recent reports of development identified for phase-I development in Hypoglycaemia(In volunteers) in USA (IM, Injection)
- 28 Jan 2018 No recent reports of development identified for phase-I development in Hypoglycaemia(In volunteers) in USA (SC, Injection)